Editors for Cancer Biology

We aim to publish conceptually important advances in all areas of cancer biology, including the discovery of new mechanisms responsible for cancer initiation, progression and therapy response. We are also interested in clinical trials or other clinical observations that reveal new and important biological insights. Read the latest research in this subject area.

Senior editors

  1. Utpal Banerjee

    University of California, Los Angeles, United States

    Utpal Banerjee is the Irving and Jean Stone Professor and Chair of the Department of Molecular, Cell and Developmental Biology at the University of California, Los Angeles, with a joint appointment in the Department of Biological Chemistry at the David Geffen School of Medicine. He also serves as Co-Director of the Broad Stem Cell Research Center and as Director of the UCLA Interdepartmental Minor in Biomedical Research. He is a member of UCLA’s Jonsson Comprehensive Cancer Center and is affiliated with the Brain Research Institute and the Neuroscience Graduate Program.

    Banerjee’s laboratory has worked on several oncogenic and metabolic signals that are important in development and disease. The lab studies the effects of systemic signals on the maintenance of blood progenitors in Drosophila, and the role of metabolic pathways in the control of proliferation and differentiation in the preimplantation mouse embryo.

    Expertise
    Developmental Biology
    Stem Cells and Regenerative Medicine
    Cancer Biology
    Research focus
    haematopoiesis
    cancer biology
    Experimental organism
    D. melanogaster
    mouse
  2. Wafik S El-Deiry

    Brown University, United States

    Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director, Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown and Lifespan. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He sees patients in his weekly clinic at Rhode Island Hospital focused on care of patients with colorectal cancer and participates in clinical trials based on his laboratory’s research on novel therapeutics. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014 Dr El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He was previously a tenured Professor of Medicine (Hematology-Oncology), Genetics, and Pharmacology at University of Pennsylvania, co-Leader of the Radiobiology and Imaging Program at the Abramson Cancer Center and Associate Director for Physician-Scientist Training in Hematology-Oncology when he left Penn in 2010. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. As a practicing academic Oncologist, his scientific interest and expertise is in cell death, drug resistance in cancer and drug discovery and development. El-Deiry founded two companies, Oncoceutics, Inc. and p53-Therapeutics, Inc.

    El-Deiry discovered p21(WAF1) as a p53 target gene, universal cell cycle inhibitor, and tumor suppressor gene that for the first time explained the mammalian cell stress response. He discovered TRAIL receptor DR5 and its regulation by p53. TRAIL is part of the host immune system that suppresses cancer and its metastases. His lab created a knock-out mouse for TRAIL receptor DR5 and this mouse is tumor prone and develops an inflammatory syndrome in the lungs and gut after sub-lethal irradiation. He identified c-Myc as a major determinant of TRAIL sensitivity and demonstrated synergy between TRAIL therapy and multi-kinase inhibitor sorafenib. Building on his prior accomplishments, El-Deiry discovered ONC201/TIC10 as a first-in-class TRAIL pathway inducer that is orally bioavailable and crosses the blood-brain barrier to treat brain tumors. TRAIL and Foxo3a are required for the anti-tumor effect of ONC201 through dual blockade of ERK and Akt kinases that promotes the nuclear translocation of the Foxo3a transcription factor which directly regulates the TRAIL gene. Data from El-Deiry’s lab identified that ONC201 induces TRAIL receptor DR5 through an integrated stress response involving ATF4 and CHOP transcription factors. Patients with among the most aggressive gliomas (H3K27M mutant DIPG) have had exceptional responses to ONC201.

    As a physician-scientist, Dr El-Deiry has worked to bring new discoveries to the clinic. He is committed in the next phase of his career to unraveling the mechanisms involved in p53 pathway restoration by candidate therapeutics his lab has discovered. This is exciting as he is defining a novel class of anti-cancer drugs with p53 pathway restoration and S-phase checkpoint targeting and recognizing ATF4 as a major transcription factor mechanism for p53 pathway restoration in p53-null or p53 mutant tumor cells. He is establishing transcriptomic and proteomic data sets with chemotherapy that acts through p53, and with novel small molecules that restore the p53 pathway in p53-deficient or mutant p53 expressing cells. He is exploiting medicinal chemistry and organoid technologies to perform his translational science that is leading to clinical trials some of which he leads. Dr El-Deiry conducts basic and translational clinical oncology therapeutics research through funded NIH grants, Foundations and industry. He is a member of the ASCI, AAP, Past President of the Interurban Clinical Club, previous Chair of ASCO’s Tumor Biology Track, and past Chair of an NIH Study Section on Cancer Therapeutics. Dr El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.

    Expertise
    Medicine
    Cancer Biology
    Research focus
    cancer
    tumor suppressor genes
    colorectal cancer
    p53 pathway
    cell death
    medical oncology
    drug development
    drug discovery
    p21(WAF1)
    ONC201/TIC10
    physician-scientist issues
    Experimental organism
    human
    mouse
    Competing interests statement
    Dr El-Deiry receives funding from the NIH/NCI, the Warren Alpert Foundation, and D&D Pharmatech. He is a Specialty Chief Editor for the Cancer Molecular Targets and Therapeutics Section of Frontiers in Oncology. He is also a Section Editor for Molecular Oncology and HemOnc Today. Dr El-Deiry is the scientific founder and shareholder of Oncoceutics, Inc. and p53-Therapeutics, Inc.
  3. Eduardo Franco

    McGill University, Canada

    Eduardo Franco is Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. He holds BSc (1975) and Licentiate (1976) degrees in biology from Universidade de Campinas, Brazil, and master's (MPH) and doctoral (DrPH) degrees in public health microbiology from the University of North Carolina at Chapel Hill (1981-84). He was a Guest Researcher at the US Centers for Disease Control in Atlanta (1980-81 and 1983-84), and a post-doctoral fellow in cancer epidemiology during 1984 at the International Agency for Research on Cancer in Lyon, France, at the US National Cancer Institute (NCI) in Bethesda, and at Louisiana State University, in New Orleans. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award, Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society, the Women in US Government’s Leadership Award, the Canadian Cancer Society’s Warwick Prize, the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics, the University of British Columbia’s Chew Wei Memorial Prize in Cancer Research, and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He has mentored 115 graduate students and post-doctoral fellows, and 30 undergraduate trainees. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. Heholds an honorary doctorate from Universidade Fernando Pessoa, Porto, Portugal.

    Expertise
    Cancer Biology
    Epidemiology and Global Health
    Medicine
    Research focus
    cancer epidemiology
    cancer prevention
    human papillomavirus
    cancer screening
    Experimental organism
    human
    Competing interests statement
    Entire research program funded by the Medical Research Council of Canada (until 1999), Canadian Institutes of Health Research (CIHR) (1999-present), National Institutes of Health, Canadian Cancer Society, and Cancer Research Society. He has received salary awards from the Fonds de Recherche Quebec Santé and CIHR. He holds a James McGill Professorship and the Minda de Gunzburg Endowed Chair at McGill University. He serves as Editor-in-Chief for Preventive Medicine and Preventive Medicine Reports and serves on the editorial boards of Cancer Epidemiology, Biomarkers & Prevention, International Journal of Cancer, Papillomavirus Research, and Salud Publica de Mexico. He has served as occasional consultant to companies involved with HPV vaccination (Merck and GSK) and HPV diagnostics (Roche, Abbott, Qiagen, and BD).
  4. Erica Golemis

    Fox Chase Cancer Center, United States

    Erica A Golemis, PhD is a Professor at Fox Chase Cancer Center (FCCC), and Adjunct Professor at the Temple University School of Medicine, the University of Pennsylvania, and the Drexel University College of Medicine. Since 2008, she has served as Co-Leader for the FCCC Molecular Therapeutics program, and as Deputy Chief Science Officer at FCCC. She is an elected Fellow of the American Association for the Advancement of Science, and holds the William Wikoff Smith Chair in Biology at Fox Chase. Dr Golemis joined FCCC in 1993, after completing graduate training in mechanisms of leukemogenesis at MIT, and postdoctoral work at Harvard Medical School and Massachusetts General Hospital leading to the development of new technology for the identification and analysis of protein interaction networks. One focus of her reserch is the targeted study of a group of oncogenes including NEDD9, AURKA, and associated proteins that regulate cell cycle and metastasis; this work has recently focused on defining non-canonical activities of these proteins in control of ciliation as a mechanism for their oncogenic effect. A second research area is the use of bioinformatics-guided and siRNA screening approaches to elucidate signaling networks that can be targeted to improve therapeutic response; this work is typically highly collaborative with clinical researchers. In the past 25 years, she has served continuously on peer-review panels for the NIH, the American Cancer Society, the DOD, the Komen Foundation, and other agencies.

    Expertise
    Cancer Biology
    Cell Biology
    Research focus
    signal transduction
    targeted therapy
    mitosis
    cilia
    polycystic kidney disease
    colorectal cancer
    head and neck cancer
    invasion
    metastasis
    Competing interests statement
    Dr Golemis currently receives funding from the National Institutes of Health (NIH) and holds editorial roles at the following journals: Cancer Biology and Therapy, Frontiers in Oncology, Gene and BMC Cancer.
  5. Caigang Liu

    Shengjing Hospital of China Medical University, China

    Caigang Liu received his PhD from the China Medical University, and trained clinically at first hospital of China Medical University. Then joined and served as a director of Breast Center Shengjing Hospital of China Medical University in 2016. His current research interests focus on clinical and translational research of oncology. In recent years, he has led a clinical research term to explore the improvement in breast reconstruction surgery and highly safe and effective anti-cancer strategies, along with identification of therapeutic targets and development of small molecular drugs against cancer metastasis. He has led several projects funded by the National Natural Science Foundation, including the discovery of FSIP1 as a new target for anti-HER2 treatment, and is developing a new strategy to reverse anti-HER2 resistance in breast cancer. He is a member of the National Micro-noninvasive Committee of Chinese Medical Association, a vice chairman of the first breast disease branch of China Sexology Association, and a member of the Standing Committee in breast cancer marker collaboration group of Chinese Anti-cancer Association.

    Expertise
    Medicine
    Cancer Biology
    Research focus
    surgical oncology
    oncological clinical trials
    breast cancer translational medicine
    cancer metastasis and drug resistance
    small molecular drug development
    Experimental organism
    human
    mouse
    Competing interests statement
    Caigang Liu is currently funded by the National Natural Science Foundation of China and “Top young talent” project of Liaoning province, China. He now holds a number of patents for anti-tumor small molecular drugs and Traditional Chinese Medicine.
  6. Tony Ng

    King's College London, United Kingdom

    Tony Ng (FMEDSCI, MB ChB, MRCP, FRCPath, PhD) brings a rich spectrum of knowledge and capabilities with clinical experience in treating AIDS patients (with opportunistic infections and cancers) and fundamental immunology skills. He is also a pioneer of molecular imaging in cancer. He was the first person to use antibody based fluorescence lifetime imaging (FLIM) approaches in tumour cells and tissues to monitor protein states and function. He has published on how to visualize protein biochemistry in preclinical models; as well as in patient-derived cancer tissues for establishing in vitro/ companion diagnostics. He has adopted a multidisciplinary approach to understand cancer recurrence and also to stratify molecularly targeted agents in combination with immunotherapy. His research bridges the gap between physics, biology and medicine, particularly in the field of translational cancer research.

    For clinical translation, he has the proven ability to coordinate and work cooperatively with colleagues and leaders in a wide variety of disciplines (imaging, cell biology, oncology, bioinformatics, surgery, pathology, genomics, as well as physical science disciplines such as mathematics, physics, chemistry and engineering). He has directed the KCL and UCL Comprehensive Cancer Imaging Centre (CCIC, one of four centres funded by CRUK & EPSRC in the UK) since its inception in 2008. The vision for the CCIC is to develop novel imaging (PET and MRI) technologies and use them in combination with clinicopathological assessment, genomics and in-house nanoscopic imaging to measure protein interactions in the context of interventional trials. In such trial context, the tissue imaging (FLIM histology) approach he has developed and refined over the years is beginning to reveal ErbB/ HER receptor rewiring as a mechanism of resistance in human tumours under selection pressure such as cetuximab.

    Tony Ng is the current Director of the Comprehensive Cancer Centre, part of the KCL School of Cancer & Pharmaceutical Sciences, and the National Institute for Health and Care Research (NIHR) Guy’s & St Thomas’ Biomedical Research Centre (BRC) Cancer Theme. In 2022, he joined GSK on a part-time basis, to help establish the GSK-KCL Translational Oncology Research Hub which was which was announced in September 2021. The aim is to apply his clinical medicine training as well as immunology, biochemistry and imaging expertise to accelerate the development of the anti-cancer drugs. HIs experience of collaborating with mathematicians/theoretical physicists creates an opportunity to bridge the biology & AI/ML interface, an essential component of delivering the innovative Digital biological twin vision.

    Training/expertise: Medicine, Immunology, Cancer cell biology, Biochemistry and Optical Imaging/Biophysics as well as preclinical Radionuclide imaging.

    Expertise
    Medicine
    Cancer Biology
    Immunology and Inflammation
    Research focus
    imaging
    biomarkers
    trial
    immune
    cancer
    reverse translation
    exosome
    organoid
    tumour microenvironment
    Competing interests statement
    At KCL, Tony Ng receives funding from Cancer Research UK, Medical Research Council, Wellcome Leap Inc., European Commission and GSK. He is employed on a part time basis as the Vice President of the Digital biological twin Unit at GSK.
  7. Päivi Ojala

    University of Helsinki, Finland
    Imperial College London, United Kingdom

    Päivi Ojala is the Professor of Cancer Cell Biology at University of Helsinki and Chair of Viral Tumorigenesis at Imperial College London. She has made significant contributions to the Kaposi’s Sarcoma herpesvirus (KSHV) field and has more recently focused also on the role of lymphatic endothelial microenvironment on cancer cell metastasis. She has expertise in organotypic 3D co-culture models, cell-based high-content screens, protein kinase signalling and viral technologies. Her work has led to demonstration of restoration of p53 function by small molecule inhibitors as a therapeutic modality for KSHV-induced lymphomas, identification of host Pim kinases, nucleophosmin, and the p53-p21 axis as novel regulators of viral replication, and shown that KSHV infection reprograms lymphatic endothelial cells (LECs) to a new, more invasive cell type. They have also demonstrated that LEC interaction with melanoma cells leads to increased distant organ metastasis in vivo, which is dependent on MMP14, Notch3 and b1-integrin- Dr. Ojala holds a doctoral degree in Molecular Genetics from the University of Helsinki, and has received postdoctoral training at the Yale School of Medicine, CT, USA.

    Expertise
    Cancer Biology
    Microbiology and Infectious Disease
    Research focus
    human tumor viruses
    virus-host interactions
    cancer metastasis
    notch signaling
    lymphatic endothelial transcription factors
    CAR T cell therapies
    Experimental organism
    human primary and cancer cells
    immunocompromised mouse
    Competing interests statement
    Päivi Ojala receives funding from the Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland and University of Helsinki.
  8. W Kimryn Rathmell

    Vanderbilt University Medical Center, United States

    Dr Kimryn Rathmell is the Chair of Medicine and Physician-in-Chief at Vanderbilt University Medical Center. She is a physician-scientist studying the molecular biology of renal cell carcinomas and rare tumors of the kidney. She earned her MD and PhD in Biophysics at Stanford University. She completed internal medicine training at the University of Chicago and the University of Pennsylvania, and fellowship in medical oncology at the University of Pennsylvania. She joined Vanderbilt in 2015 to lead the Division of Hematology and Oncology.

    Her research program focuses on understanding the molecular pathogenesis of renal cell carcinomas and spans early models of renal tumorigenesis, novel imaging strategies for diagnosis and screening of kidney cancer, epigenetic regulation of kidney cancers, metabolic features of tumorigenesis, and novel therapeutic strategies to overcome resistance to anti-angiogenic therapy and checkpoint targeted immunotherapy. With these bench to bedside strategies, her laboratory endeavors to integrate knowledge of pathways that promote cancer development with translational clinical studies, and uses these discoveries to develop robust approaches to improve the survival of patients with kidney cancers. She serves as the Deputy Director for Research Integration and Career Development for the Vanderbilt-Ingram Cancer Center and on the Board of Scientific Advisors for the National Cancer Institute.

    Expertise
    Cancer Biology
    Medicine
    Research focus
    cancer biology
    molecular biology
    epigenetics
    biomarkers
    angiogenesis
    Competing interests statement
    Stock and Other Ownership Interests
    Company: Sitryx (Recipient: An Immediate Family Member); Company: Caribou Publishing (Recipient: An Immediate Family Member); Company: Nirogy Therapeutics (Recipient: An Immediate Family Member)Honoraria
    Company: Merck (Recipient: An Immediate Family Member); Company: Pfizer (Recipient: An Immediate Family Member)Consulting or Advisory Role
    Company: Sitryx (Recipient: An Immediate Family Member); Company: caribou Biosciences (Recipient: An Immediate Family Member)Research Funding
    Company: Incyte (Recipient: An Immediate Family Member); Company: Calithera Biosciences (Recipient: An Immediate Family Member); Company: Tempus (Recipient: An Immediate Family Member); Company: Peloton Therapeutics (Recipient: Institution); Company: Pfizer (Recipient: Institution); Company: Genentech (Recipient: Institution); Company: E.R. Squibb Sons, LLC (Recipient: Institution)Patents, Royalties, Other Intellectual Property
    ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapyOpen Payments Link
  9. Richard M White

    Memorial Sloan Kettering Cancer Center, United States

    Richard White, M.D., Ph.D, is a physician-scientist at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interested in basic mechanisms underlying metastasis, using the zebrafish as a model system. His work has established numerous techniques for cancer modeling and high-resolution imaging in the fish. Using these tools, the lab is focused on the cross-talk between tumor cells and the microenvironment, and how this interplay influences metastatic success. His work has revealed novel interactions between melanoma cells and adipocytes in the microenvironment, and how neural crest programs play roles in melanoma progression. He has been awarded the NIH Director’s New Innovator Award, the Pershing Square Foundation Award, and the Mark Foundation ASPIRE award.

    Expertise
    Cancer Biology
    Cell Biology
    Developmental Biology
    Medicine
    Research focus
    development
    neural crest
    zebrafish
    cancer
    melanoma
    metastasis
    microenvironment
    Experimental organism
    zebrafish
    Competing interests statement
    Richard White receives funding from the National Institutes of Health, the Pershing Square Sohn Foundation, the Mark Foundation, the Melanoma Research Alliance, the American Cancer Society and the Harry J. Lloyd Foundation. He receives consulting fees from N-of-One, Inc.

Reviewing editors

  1. Nicola Aceto

    Swiss Federal Institute of Technology in Zurich, Switzerland

    Expertise
    Cancer Biology
    Research focus
    disseminated tumor cells
    circulating tumor cells
    cancer progression
    metastasis
  2. Wadih Arap

    Rutgers Cancer Institute of New Jersey at University Hospital, United States

    Expertise
    Medicine
    Cancer Biology
    Research focus
    clinical oncology
    genitourinary (GU) cancers
    prostate cancer
  3. Robert Baiocchi

    The Ohio State University, United States

    Expertise
    Medicine
    Cancer Biology
    Immunology and Inflammation
    Research focus
    Epstein Barr Virus
    lymphoma
    cancer therapeutics
    cancer vaccines
    cancer immunology
    cancer immunotherapy
    cancer epigenetics
  4. Muthuswamy Balasubramanyam

    Madras Diabetes Research Foundation, India

    Expertise
    Medicine
    Biochemistry and Chemical Biology
    Cancer Biology
    Cell Biology
    Developmental Biology
    Epidemiology and Global Health
    Genetics and Genomics
    Immunology and Inflammation
    Neuroscience
    Stem Cells and Regenerative Medicine
    Research focus
    disease biology
    diabetes
    aging
    omnics
    calcium signaling
    endocrine disruptors
    probiotics
    molecular medicine
  5. Nicholas Banovich

    Translational Genomics Research Institute (TGen), United States

    Expertise
    Cancer Biology
    Genetics and Genomics
    Chromosomes and Gene Expression
    Research focus
    single cell biology
    CAR T cell therapy
    gene regulation
    pulmonary fibrosis
    quantitative trait loci
  6. Frederic A Bard

    Institute of Molecular and Cell Biology (A*STAR), Singapore

    Expertise
    Cell Biology
    Cancer Biology
    Research focus
    Golgi
    protein glycosylation
    signaling
    cancer
    matrix degradation
    cell migration
    Experimental organism
    human
    mouse
  7. Anton M Bennett

    Yale University, United States

    Expertise
    Cell Biology
    Biochemistry and Chemical Biology
    Cancer Biology
    Research focus
    cell signalling
    metabolism
    protein tyrosine phosphorylation
    protein tyrosine kinases
    protein tyrosine phosphatases
  8. Philip Boonstra

    University of Michigan, United States

    Expertise
    Medicine
    Epidemiology and Global Health
    Cancer Biology
    Genetics and Genomics
    Research focus
    biostatistics
    clinical trials
    cancer biostatistics
    epidemiology
    ECMO
    statistical programming
  9. Dirce M Carraro

    AC Camargo Cancer Center, Brazil

    Expertise
    Medicine
    Cancer Biology
    Research focus
    oncology
    cancer genomics
  10. Nyasha Chambwe

    St Jude Children's Research Hospital, United States

    Expertise
    Cancer Biology
    Computational and Systems Biology
    Genetics and Genomics
    Research focus
    bioinformatics
    computational biology
    cancer genomics
    population genomics
    data analysis
    Experimental organism
    human
  11. Jungmin Choi

    Korea University College of Medicine, South Korea

    Expertise
    Cancer Biology
    Computational and Systems Biology
    Genetics and Genomics
    Medicine
    Research focus
    rare disorders
    single cell genomics
    computational biology
    human genomics
  12. Leslie D Cope

    Johns Hopkins University, United States

    Expertise
    Cancer Biology
    Computational and Systems Biology
    Genetics and Genomics
    Research focus
    bioinformatics
    biostatistics
    high-throughput genomic data
    methods for identifying and validating biomarkers
  13. Seth J Corey

    Cleveland Clinic, United States

    Expertise
    Cancer Biology
    Medicine
    Research focus
    myeloid malignancies
    inherited or acquired bone marrow failure
    neutrophils
    platelets zebrafish
    cancer evolution
    proteostasis
  14. Maximiliano A D'Angelo

    Sanford Burnham Prebys Medical Discovery Institute, United States

    Expertise
    Cancer Biology
    Cell Biology
    Immunology and Inflammation
    Research focus
    nuclear pore complex
    nuclear transport
    importin
    exportin
    immunology
    cancer
    muscle
  15. Yamini Dalal

    National Cancer Institute, United States

    Expertise
    Cancer Biology
    Chromosomes and Gene Expression
    Genetics and Genomics
    Research focus
    chromatin
    centromeres
    chromosomes
    mitosis
    chromosome cancer biology
    histone variants
    nucleosomes
    Experimental organism
    human
    mouse
  16. Irwin Davidson

    Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/UDS, France

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Chromosomes and Gene Expression
    Research focus
    transcription
    chromatin
    genomics
    cancer
    Experimental organism
    human
    mouse
  17. Melissa J Davis

    The Walter and Eliza Hall Institute of Medical Research, Australia

    Expertise
    Computational and Systems Biology
    Cancer Biology
    Cell Biology
    Genetics and Genomics
    Research focus
    bioinformatics
    computational biology
    network analysis
    network inference
    transcriptomics
    molecular phenotype prediction
    epithelial-mesenchymal transition
  18. Roger J Davis

    University of Massachusetts Medical School, United States

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Cell Biology
    Research focus
    diabetes
    NAFLD
    NASH
    metabolism
    insulin resistance
    cancer
    signal transduction
    Experimental organism
    mouse
    human
  19. Emek Demir

    Oregon Health and Science University, United States

    Expertise
    Cancer Biology
    Computational and Systems Biology
    Genetics and Genomics
    Medicine
    Research focus
    proteomics
  20. Gina M DeNicola

    Moffitt Cancer Center, United States

    Expertise
    Cancer Biology
    Biochemistry and Chemical Biology
    Research focus
    tumor metabolism
    redox biology
    ROS
    sulfur metabolism
    NRF2/KEAP1
    mouse models of cancer
  21. Ivan Dikic

    Goethe University Frankfurt, Germany

    Expertise
    Biochemistry and Chemical Biology
    Cell Biology
    Cancer Biology
    Microbiology and Infectious Disease
    Research focus
    ubiquitination
    autophagy
    ER remodelling
    infection
    virus
    bacteria
    cancer
    Experimental organism
    mouse
    C. elegans
    S. cerevisiae
  22. Martin Eilers

    University of Würzburg, Germany

    Expertise
    Cancer Biology
    Research focus
    Myc proteins
    Myc function
    Targeting N-MYC/AURORA for tumor therapy
    Myc and Ubiquitin
    Experimental organism
    human
  23. Eduardo Eyras

    Australian National University, Australia

    Expertise
    Genetics and Genomics
    Cancer Biology
    Chromosomes and Gene Expression
    Computational and Systems Biology
    Research focus
    bioinformatics
    transcriptomics
    long-read sequencing technologies
    RNA splicing
    alternative splicing
    nanopore
  24. Lydia W S Finley

    Memorial Sloan Kettering Cancer Center, United States

    Expertise
    Cell Biology
    Cancer Biology
    Stem Cells and Regenerative Medicine
    Research focus
    cell metabolism
    cancer
    stem cells
    epigenetics
    cell fate
  25. Stacey D Finley

    University of Southern California, United States

    Expertise
    Medicine
    Computational and Systems Biology
    Cancer Biology
    Research focus
    mathematical modeling
    multiscale models
    biochemical signal transduction networks
  26. Margaret Frame

    University of Edinburgh, United Kingdom

    Expertise
    Cancer Biology
    Research focus
    cancer
    cell adhesion networks
    nodal tyrosine kinases
  27. Michael R Green

    University of Massachusetts Medical School, United States

    Expertise
    Cancer Biology
    Chromosomes and Gene Expression
    Medicine
    Research focus
    transcription
    pre-mRNA splicing
    cancer molecular biology
    oncology
    genetics
    functional genomics
    Experimental organism
    human
    mouse
    S. cerevisiae
  28. Yogesh K Gupta

    The University of Texas Health Science Center at San Antonio, United States

    Expertise
    Medicine
    Structural Biology and Molecular Biophysics
    Cancer Biology
    Microbiology and Infectious Disease
    Research focus
    drug discovery
    nucleic acid modifications
    cancer epigenetics
    structures of viral proteins
    host-pathogen interactions
  29. William C Hahn

    Dana-Farber Cancer Institute, United States

    Expertise
    Cancer Biology
    Genetics and Genomics
    Medicine
    Research focus
    cancer
    transformation
    functional genomics
    RAS
    YAP1
    Experimental organism
    human
  30. Elizabeth P Henske

    Brigham And Women's Hospital, United States

    Expertise
    Medicine
    Cancer Biology
    Research focus
    tuberous sclerosis complex
    lymphangioleiomyomatosis
    mTOR
    prostate cancer
  31. Ping-Chih Ho

    Ludwig Institute for Cancer Research, Switzerland

    Expertise
    Cancer Biology
    Immunology and Inflammation
    Cell Biology
    Research focus
    immunometabolism
    cancer immunology
    tumor microenvironment
    immunotherapy
    adaptive immunity
    macrophages
    metabolic disease
    Experimental organism
    mouse
  32. Wenwei Hu

    Rutgers University, United States

    Expertise
    Cancer Biology
    Research focus
    p53 signaling
    tumor suppressors
    cancer metabolism
    cancer cell biology
    signal transduction
    Experimental organism
    human
    mouse
  33. Tony Hunter

    Salk Institute for Biological Studies, United States

    Expertise
    Cancer Biology
    Cell Biology
    Research focus
    cancer
    signal transduction
    phosphorylation
    ubiquitylation
    sumoylation
    Experimental organism
    mouse
    yeast
  34. Arezu Jahani-Asl

    McGill University, Canada

    Expertise
    Cancer Biology
    Cell Biology
    Developmental Biology
    Research focus
    glioblastoma
    stem cells
    mitochondria
    transcription
    mental retardation
    neurodegeneration
    cancer
    Experimental organism
    mouse
  35. Jean Jiang

    The University of Texas Health Science Center at San Antonio, United States

    Expertise
    Medicine
    Cell Biology
    Cancer Biology
    Research focus
    gap junctions
    hemichannels
    connexins
    bone biology
    osteocyte
    bone mechanobiology
    cancer bone metastasis
    lens biology
  36. Gou Young Koh

    Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST), South Korea

    Expertise
    Cancer Biology
    Developmental Biology
    Research focus
    angiogenesis
    lymphangiogenesis
    adipogenesis
    cardiogenesis
    vascular and cardiovascular biology
  37. Ashish Lal

    National Institutes of Health, United States

    Expertise
    Cancer Biology
    Biochemistry and Chemical Biology
    Chromosomes and Gene Expression
    Genetics and Genomics
    Research focus
    RNA biology
    lncRNAs
    microRNAs
    gene regulation
    cancer biology
    p53
    Experimental organism
    human
  38. Beate Lichtenberger

    Medical University of Vienna, Austria

    Expertise
    Cancer Biology
    Stem Cells and Regenerative Medicine
    Research focus
    Cancer-associated fibroblasts (CAFs)
    fibroblast-mediated skin pathologies
    skin cancer
    stem cell fate decisions
    Experimental organism
    human
    mouse
  39. Yuting Ma

    Suzhou Institute of Systems Medicine, China

    Expertise
    Cancer Biology
    Immunology and Inflammation
    Cell Biology
    Research focus
    tumor immunology
    immunotherapy
    tumor microenvironment
    stress responses
    neuroendocrine-immune crosstalk
    cell death
  40. Kay F Macleod

    University of Chicago, United States

    Expertise
    Cell Biology
    Cancer Biology
    Research focus
    autophagy
    mitochondria
    pancreatic cancer
    breast cancer
    liver homeostasis
    tumor metabolism
    Experimental organism
    mouse
    human
  41. Jean-Christophe Marine

    Vlaams Instituut voor Biotechnologie, Belgium

    Expertise
    Cancer Biology
    Genetics and Genomics
    Research focus
    mouse genetics
    molecular oncology
    cancer genomics
    Experimental organism
    mouse
  42. Rui Medeiros

    Instituto Português de Oncologia-Porto, Portugal

    Expertise
    Medicine
    Cancer Biology
    Research focus
    oncology
    molecular oncology
    viral pathology
  43. Simón Méndez-Ferrer

    University of Cambridge, United Kingdom

    Expertise
    Stem Cells and Regenerative Medicine
    Developmental Biology
    Cancer Biology
    Medicine
    Research focus
    haematopoietic stem cell niche
    mesenchymal stem cells
    myeloproliferative neoplasms
    acute myeloid leukemia
    neuroimmunology
  44. Goutham Narla

    University of Michigan, United States

    Expertise
    Medicine
    Cancer Biology
    Genetics and Genomics
    Research focus
    cancer therapeutics
    cancer genetics
    small molecule drug development
    protein phosphatase
    Experimental organism
    human
    mouse
  45. Duojia Pan

    UT Southwestern Medical Center, United States

    Expertise
    Cancer Biology
    Cell Biology
    Research focus
    growth control
    tumor suppressors
    oncogenes
    Hippo signaling
    transcription
    regeneration
    Experimental organism
    D. melanogaster
    mouse
  46. Maddy Parsons

    King's College London, United Kingdom

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Cell Biology
    Physics of Living Systems
    Research focus
    adhesion
    migration
    cytoskeleton
    receptor signalling
    extracellular matrix
    fibrosis
    cancer
    Experimental organism
    mouse
  47. Renata Pasqualini

    Rutgers University, United States

    Expertise
    Medicine
    Cancer Biology
    Research focus
    radiation oncology
    translational cancer research
    prostate cancer
    vascular biology
  48. Lynne-Marie Postovit

    University of Alberta, Canada

    Expertise
    Cancer Biology
    Cell Biology
    Stem Cells and Regenerative Medicine
    Research focus
    cellular plasticity
    tumour microenvironment
    hypoxia
    stem cells
    metastasis
    ovarian cancer
    breast cancer
  49. Michaela Reagan

    Maine Medical Center Research Institute, United States

    Expertise
    Medicine
    Cancer Biology
    Cell Biology
    Stem Cells and Regenerative Medicine
    Research focus
    multiple myeloma
    bone marrow adipocyte
    fatty acid binding protein
    cancer-induced bone disease
    osteolysis
    Experimental organism
    mouse
  50. Charles Sawyers

    Memorial Sloan-Kettering Cancer Center, United States

    Expertise
    Cancer Biology
    Medicine
    Research focus
    translational medicine
    oncology
    Experimental organism
    human
  51. Ernestina Schipani

    University of Pennsylvania, United States

    Expertise
    Medicine
    Stem Cells and Regenerative Medicine
    Cell Biology
    Developmental Biology
    Cancer Biology
    Research focus
    hypoxia
    hypoxia-inducible factors
    mitochondria
    skeleton
    chondrocytes
    bone
    G protein-coupled receptors (GPCR)
  52. Katharina Schlacher

    UT MD Anderson Cancer Center, United States

    Expertise
    Cancer Biology
    Chromosomes and Gene Expression
    Research focus
    mitochondria
    mitochondrial DNA replication
    mitochondrial instability
    cGAS
    inflammation
    inflammation signaling
    inflammasome
    Fanconi Anemia
  53. Jeffrey Settleman

    Pfizer, United States

    Expertise
    Cancer Biology
    Research focus
    cancer cell biology
    signal transduction
    tumor heterogeneity
    signaling
    epigenetics
  54. Nima Sharifi

    Cleveland Clinic, United States

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Medicine
    Research focus
    steroid biochemistry
    steroid metabolism
    prostate cancer
    nuclear receptors
    hormone therapy resistance
    androgens
    oncology
    Experimental organism
    mouse
  55. Maria Spies

    University of Iowa, United States

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Chromosomes and Gene Expression
    Structural Biology and Molecular Biophysics
    Research focus
    single-molecule biophysics
    DNA repair
    DNA replication
    DNA recombination
    genome stability
    protein dynamics
    protein-nucleic acids interactions
    drug discovery
    Experimental organism
    human
    yeast
    bacteria
  56. Margaret Stanley

    University of Cambridge, United Kingdom

    Expertise
    Cancer Biology
    Microbiology and Infectious Disease
    Medicine
    Epidemiology and Global Health
    Research focus
    vaccines
    cervix cancer
    cervix precancer
    keratinocyte biology
    human papillomavirus
    DNA viruses
    vaccine immunology
    Experimental organism
    human
  57. Ivan Topisirovic

    Jewish General Hospital, Canada

    Expertise
    Biochemistry and Chemical Biology
    Cancer Biology
    Cell Biology
    Research focus
    mRNA translation
    signaling
    metabolic regulation
    protein quality control
    Experimental organism
    mouse
    human
  58. Samra Turajlic

    The Francis Crick Institute, United Kingdom

    Expertise
    Medicine
    Cancer Biology
    Research focus
    medical oncology
    cancer genetics
    tumour heterogeneity
    melanoma
    kidney cancer
    Experimental organism
    human
  59. Eric J Wagner

    University of Texas Medical Branch at Galveston, United States

    Expertise
    Chromosomes and Gene Expression
    Biochemistry and Chemical Biology
    Cancer Biology
    Genetics and Genomics
    Research focus
    RNA biology
    transcription
    RNA processing
    gene expression
  60. Linghua Wang

    The University of Texas MD Anderson Cancer Center, United States

    Expertise
    Cancer Biology
    Computational and Systems Biology
    Genetics and Genomics
    Immunology and Inflammation
    Medicine
    Research focus
    computational biology
    cancer immunogenomics
    cancer genomics
  61. Jian Xu

    University of Texas Southwestern Medical Center, United States

    Expertise
    Cancer Biology
    Chromosomes and Gene Expression
    Developmental Biology
    Genetics and Genomics
    Stem Cells and Regenerative Medicine
    Research focus
    hematopoiesis
    erythropoiesis
    myeloid leukemia
    epigenetics
    transcription regulation
    enhancer
    metabolism
    Experimental organism
    human
    mouse
  62. Norma Ybarra

    Research Institute McGill University Health Center, Canada

    Expertise
    Cancer Biology
    Stem Cells and Regenerative Medicine
    Research focus
    radiation biology
    radiotherapy
    cancer cell metabolism
    cancer therapies
  63. Keqiang Ye

    Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, China

    Expertise
    Medicine
    Cancer Biology
    Biochemistry and Chemical Biology
    Neuroscience
    Research focus
    neuroscience
    molecular cytobiology
    cancer biology
    neurodegenerative disease
    Experimental organism
    mouse
  64. Chunling Yi

    Georgetown University, United States

    Expertise
    Cancer Biology
    Cell Biology
    Chromosomes and Gene Expression
    Genetics and Genomics
    Research focus
    cancer signaling
    mouse models
    drug resistance
    transcription regulation
  65. Qing Zhang

    University of Texas Southwestern Medical Center, United States

    Expertise
    Cancer Biology
    Biochemistry and Chemical Biology
    Research focus
    CRISPR
    cancer metabolism
    hypoxia
    kidney cancer
    breast cancer
    epigenetics
    post-translational modifications
    synthetic lethality
  66. Shengtao Zhou

    Sichuan University West China Second University Hospital, China

    Expertise
    Cancer Biology
    Medicine
    Research focus
    gynecologic oncology
    cancer biology
    tumor immunology
    metabolism
    nuclear receptors
    systems biology
    Experimental organism
    human
    mouse
  67. Hao Zhu

    University of Texas Southwestern Medical Center, United States

    Expertise
    Cancer Biology
    Stem Cells and Regenerative Medicine
    Medicine
    Research focus
    mechanisms of tissue repair and organ regeneration
    liver cancer
    hepatocellular carcinoma
    epigenetics
    polyploidy
    Experimental organism
    human
    mouse
  68. Wilbert Zwart

    Netherlands Cancer Institute, Netherlands

    Expertise
    Cancer Biology
    Medicine
    Research focus
    breast cancer
    prostate cancer
    hormonal regulation
    epigenetics
    transcription factors
    genomic profiling
    Experimental organism
    human